MTA3 was initially identified in breast cancer as an estrogen receptor (ER)-regulated inhibitor involved in the ER-dependent downregulation of the Snail-mediated inhibition of E-cadherin [14]. The gene discussed is CDH1; the disease is breast carcinoma.